Abstract Number: 1787 • ACR Convergence 2022
The Impact of Topically Applied pH Modulator on Acute Inflammatory Pain, Serum Calcium, and C-Reactive Protein (CRP) During an Acute Gout Flare – a Phase 2a Randomized, Double-Blind, Placebo-Controlled Study
Background/Purpose: Inflammatory cytokine-mediated bone resorption increases serum calcium (Ca2+) and can lead to calcification at chronically inflamed sites. Ca2+ influences cytokine activity to intensify the…Abstract Number: 1789 • ACR Convergence 2022
Gout in Heart Failure Patients with Left Ventricular Assist Device Therapy in a Tertiary Academic Hospital
Background/Purpose: Gout is one of the most common inflammatory joint diseases and is a disabling complication in patients with heart failure. Patients with gout and…Abstract Number: 1791 • ACR Convergence 2022
Point-of-Care Multi-Energy Photon-Counting CT for Earlier Non-Invasive Diagnosis of Gout and Calcium Pyrophosphate Deposition Disease
Background/Purpose: While the definitive diagnosis of gout and calcium pyrophosphate deposition disease (CPPD) is still based on the identification of characteristic crystals in synovial fluid…Abstract Number: 1792 • ACR Convergence 2022
Contemporary Racial/Ethnic Disparities in Emergency Department Visits and Hospitalizations for Gout in the United States – 2019 Nationwide Analysis
Background/Purpose: Gout is a highly prevalent inflammatory arthritis with increasing global disease burden in recent years.1,2 A recent analysis3 of the Multiethnic Cohort Study reported…Abstract Number: 1793 • ACR Convergence 2022
Prevalence of HLA B*5801 Allele Among African American Patients with Gout in an Academic Health Center
Background/Purpose: The presence of the HLA-B*5801 allele is strongly associated with Allopurinol Hypersensitivity Syndrome (AHS) manifesting as severe cutaneous adverse reactions (SCARs) like Drug rash…Abstract Number: 1794 • ACR Convergence 2022
Characteristics of Patients with Repeat Visits for Acute Gout at a University Hospital Emergency Department
Background/Purpose: Gout is the most common inflammatory arthritis in adults that results in high disease burden and health care utilization. The objective of the study…Abstract Number: 1796 • ACR Convergence 2022
Peripheral Vascular Disease and Sequelae in Individuals with Gout, Diabetes, or Both Among US Veterans
Background/Purpose: Peripheral vascular disease (PVD) causes substantial morbidity and mortality. Patients with gout are known to have increased coronary artery disease risk but less is…Abstract Number: 1797 • ACR Convergence 2022
Factors Driving Opioid Use in United States Veterans with Gout
Background/Purpose: Patients with gout often seek care for painful flares and nearly one-third are prescribed opioids during acute ambulatory visits. Unfortunately, opioids do not address…Abstract Number: 1798 • ACR Convergence 2022
Health-Related Quality of Life Improvements Resulting from a Treat-to-Target Strategy in the Management of Gout: Post- Hoc Analysis of a Multicenter, Randomized, Double-Blind, Non-Inferiority Trial
Background/Purpose: The ACR recommends a treat-to-target strategy in gout management, centered on the titration of urate lowering therapy (ULT) to a goal serum urate (SU)…Abstract Number: 1799 • ACR Convergence 2022
Evaluation of Adherence to and Agreement with the 2020 American College of Rheumatology Guideline for the Management of Gout by US Rheumatologists
Background/Purpose: The American College of Rheumatology (ACR) developed an updated guideline in 2020 for the management of gout.1 This study evaluates US rheumatologists' stated adherence…Abstract Number: 1800 • ACR Convergence 2022
Successful Establishment of Chronic Gouty Arthritis Model in C57BL/6 Mice
Background/Purpose: Gout is an inflammatory disease caused by the deposition of MSU crystals in joints and other parts. At present, little progress in the research…Abstract Number: 1802 • ACR Convergence 2022
The Utility of Dual-energy Computed Tomography in Gout Patients During Urate Lowering Therapy
Background/Purpose: To investigate whether monosodium urate (MSU) deposition measured by dual-energy computed tomography (DECT) could help predict acute flares after discontinuing colchicine prophylaxis in patients…Abstract Number: 1803 • ACR Convergence 2022
Neutrophil-to-lymphocyte Ratio Among Flaring and Non-flaring Uncontrolled Gout Patients Undergoing Pegloticase Therapy as Part of the Phase 3 Pivotal Trials
Background/Purpose: Gout flares result from an innate immune response against monosodium urate crystal deposits, resulting in macrophage crystal phagocytosis and cellular activation.1 NLRP3 inflammasome activation…Abstract Number: 1805 • ACR Convergence 2022
Effect of Short-Term Fruit Juice and Sugared Beverage Intake on Risk of Recurrent Gout Flares
Background/Purpose: Habitual fructose-rich beverage intake has been associated with increased serum urate (SU) levels and prevalent and incident gout. This is likely because fructose induces…Abstract Number: 1806 • ACR Convergence 2022
Characteristics and Comorbidity Burden of Phase 3 Clinical Trial Participants Who Did and Did Not Experience Acute Gout Flares During Biweekly Pegloticase Dosing
Background/Purpose: Acute gout flare often accompanies urate-lowering therapy initiation and is the most common adverse event associated with pegloticase, a recombinant pegylated uricase that rapidly…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 83
- Next Page »
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 83
- Next Page »
Didn't find what you were looking for? Try the Advanced Search »